Abstract: Slide Presentations |

Aerosolized Tobramycin Improves Outcomes in VAP Caused by Enteric Gram-Negative Bacteria in Trauma Patients FREE TO VIEW

Akella Chendrasekhar, MD; James Costa, MD; James Hopkins, MD
Author and Funding Information

Iowa Methodist Medical Center, Des Moines, IA


Chest. 2003;124(4_MeetingAbstracts):79S. doi:10.1378/chest.124.4_MeetingAbstracts.79S-a
Text Size: A A A
Published online


PURPOSE:  Late onset ventilator associated pneumonia (VAP) caused by enteric gram negative bacteria has an attributable mortality ranging from 10-60%. This high mortality rate despite the use of multiple IV antibiotics has led to speculation regarding the inability of IV antibiotics to reach the lungs. Data regarding the use of aerosolized tobramycin (TOBI) in VAP is sparce.

METHODS:  We performed a retrospective analysis of a case controlled utilization study of TOBI in VAP caused by enteric gram negative bacteria (microbiologically documented). Trauma patients diagnosed with VAP (by quantitative microbiologic techniques) were pulled from our trauma registry database and a detailed chart review was performed. All patients received either 2 IV antibiotics (Control group-n=25) or 1 IV antibiotic and TOBI (Study group-n=24). Demographic and outcome data were collected and analyzed for statistical significance.

RESULTS:  Demographic data (gender, age, injury severity score (ISS), and APACHE-2 score at the time of diagnosis of VAP) were statistically comperable between the control and study groups (Table 1)

Demographic data

Male/Female ratioAgeISSAPACHE-2Control group n=2520/537 ± 1825.1 ± 9.523.7 ± 4.9Study group n=2417/744 ± 1922.8 ± 12.322.5 ± 5.6. Outcome data (ICU length of stay, ventilator days, and hospital length of stay) showed significant reductions. Overall survival to hosptal discharge was not signifcantly different (Table 2)

Outcome data

ICU Length of Stay (days)Ventilator daysHospital Length of Stay (days)Survival (%)Control group n=2516.0 ± 7.115.4 ± 6.521.8 ± 7.480Study group11.1 ± 5.49.9 ± 3.316.3 ± 5.491 n=24*p<0.05*p<0.05*p<0.05CONCLUSIONS: In clinically matched trauma patients with VAP caused by enteric gram negative bacteria the use of aerosolized tobramycin (TOBI) seems to improve clinical outcomes.

CLINICAL IMPLICATIONS:  TOBI may be a useful tool in the treatment of VAP caused by enteric gram negative bacteria.

DISCLOSURE:  A. Chendrasekhar, CHIRON, discussion of product research or unlabeled uses of product.

Monday, October 27, 2003

8:00 AM - 9:30 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543